



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 76-332

Food and Drug Administration  
Rockville MD 20857

JUL 29 2004

Ranbaxy, Inc.  
Attention: Abha Pant  
U.S. Agent for: Ranbaxy Laboratories Limited  
600 College Road East  
Princeton, NJ 08540

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 26, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Fluconazole for Oral Suspension, 10 mg/mL (50 mg/5 mL), and 40 mg/mL (200 mg/5 mL).

Reference is also made to the Tentative Approval letters issued by this office on July 11, 2003, and April 27, 2004, and to your amendments dated December 12, 2002; and May 3, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Fluconazole for Oral Suspension, 10 mg/mL and 40 mg/mL, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Diflucan<sup>®</sup> for Oral Suspension, 10 mg/mL and 40 mg/mL, respectively, of Pfizer Central Research). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.


Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Division of Drug Marketing, Advertising, and Communications, HFD-42  
5600 Fishers Lane  
Rockville, MD 20857

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications (HFD-42) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours, 

(b)(6)

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research